| Trial ID: | L1534 |
| Source ID: | NCT00852787
|
| Associated Drug: |
Digoxin Immune Fab
|
| Title: |
Marinobufagenin as a Target for DIGIBIND in Hypertensive Patients With End-stage Renal Disease
|
| Acronym: |
|
| Status: |
UNKNOWN
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Hypertension|Hemodialysis
|
| Interventions: |
DRUG: Digoxin immune fab|DRUG: Placebo
|
| Outcome Measures: |
Primary: Blood pressure, Screening, and 24-hour period after first infusion and after second infusion | Secondary: Marinobufagenin levels, Screening, and after first and second infusions
|
| Sponsor/Collaborators: |
Sponsor: National Institute on Aging (NIA) | Collaborators: University of Toledo Health Science Campus
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
30
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2009-04
|
| Completion Date: |
2012-05
|
| Results First Posted: |
|
| Last Update Posted: |
2012-05-25
|
| Locations: |
University of Toledo Medical Center, Toledo, Ohio, 43614, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT00852787
|
